Zhengye Biotechnology Holding Limited (ZYBT) Stock

About Zhengye Biotechnology Holding Limited

Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.

Zhengye Biotechnology Holding Limited is led by CEO Songlin Song, employs 278 people, headquartered in CN, publicly traded since 2025.

Zhengye Biotechnology Holding Limited (ZYBT) stock trades at $1.89 with a market capitalization of $89.57M. The stock is valued at a price-to-earnings (P/E) ratio of -8.55, price-to-book of 2.42, price-to-sales of 7.54. Over the past 52 weeks the stock has ranged between $0.62 and $13.08, and currently trades 85.6% below its 52-week high.

On profitability, Zhengye Biotechnology Holding Limited generates a return on equity (ROE) of -26.78%, return on capital employed of -19.52%, an operating margin of -77.04%, a net profit margin of -89.05%.

Official website: www.jlzybio.com